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P atients with diabetes are at a twofold to fourfold higher risk of cardiovascular disease (CVD) compared with their counterparts (1) (2) (3) . In general, primary prevention measures using aspirin therapy have been found to be beneficial in those at high risk of CVD in the general population, although the evidence is mixed for patients with diabetes (4) (5) (6) (7) . Whether the cardiovascular benefit of aspirin for primary prevention exceeds the risk of bleeding (i.e., clinical net benefit) must be considered in clinical practice (8) . In fact, previous literature has suggested that patients with diabetes may respond less to aspirin therapy, and therefore the risk of bleeding may outweigh the benefit (5) . This possibility has resulted in inconsistent recommendations from different professional societies around the world regarding the appropriate use of aspirin for primary CVD prevention in adults with diabetes (6, (9) (10) (11) . From a clinical perspective, if platelets do not respond as well to aspirin therapy in patients with diabetes compared with those without diabetes, aspirin may not be a preferred primary prevention therapy for this population.
The notion of "aspirin resistance" in patients with diabetes has been debated in the literature, partly because of inconsistency in definitions used. Clinical aspirin resistance commonly refers to the ineffectiveness of aspirin therapy in reducing cardiovascular events and can be influenced by multiple factors, such as lack of adherence to therapy, reduced oral bioavailability with enteric coated aspirin, or interactions with medications such as nonsteroidal anti-inflammatory drugs, resulting in an overestimation of the prevalence of aspirin resistance (12) (13) (14) (15) (16) . Physiological aspirin resistance refers to the failure of aspirin therapy to fully inhibit platelet aggregation according to platelet function measures (17) . This latter definition is more specific, widely accepted, and sometimes called "high on-treatment platelet reactivity." Surprisingly, few studies have specifically investigated the effectiveness of aspirin in reducing platelet aggregation in people with diabetes, although the implications for clinical practice are substantial.
The primary effect of aspirin in reducing platelet aggregation is attributed to its ability to block the cyclooxygenase-1 (COX-1) pathway and prevent the conversion of arachidonic acid (AA) to thromboxane A2. The inability of aspirin to fully inhibit COX-1-dependent platelet activation (i.e., high on-treatment platelet reactivity) is uncommon (18) . Laboratory methods used to assess platelet aggregation in response to aspirin therapy vary across studies, contributing to the inconsistent estimations of high on-treatment platelet reactivity in diabetes (19) . COX-1-dependent platelet activation in vitro is best assessed by aggregation responses to AA, whereas in vivo activation related to COX-1 can be assessed by urinary excretion of thromboxane B2 (TXB2) (20) (21) (22) . However, platelets may also be activated in pathways that are only partly related or independent of COX-1 (23) . Analyzing markers of both in vivo and in vitro platelet activation, including pathways that are directly and indirectly related to COX-1, can give a more complete characterization of platelet function and physiological response to aspirin.
In this study, we sought to investigate the following hypotheses: multiple measures of both in vivo and in vitro platelet activation differ by diabetes status before aspirin therapy; the change in these platelet measures (platelet response) also differs by diabetes status after aspirin therapy; and the differences in aspirin's inhibitory effect by diabetes status are independent of demographic and clinical factors. We explored our hypotheses in the Genetic Study of Aspirin Responsiveness (GeneSTAR) cohort of patients at high risk based on family history of early-onset CVD.
Materials and Methods
Study participants were already enrolled as part of the GeneSTAR cohort, a study designed to examine gene-environment determinants of platelet response to low-dose aspirin. Eligible participants included unaffected, apparently healthy siblings of patients with documented coronary heart disease events before 60 years of age, along with the index patients' and siblings' adult offspring and the offspring's other parents, previously demonstrated to be at high risk of CVD (24) . All participants (n = 2113) were aged $21 years and had no coronary disease, vascular thrombotic events, peripheral vascular disease, serious gastrointestinal disorders, autoimmune diseases, bleeding disorders, or hemorrhagic events. Participants were ineligible if they were taking anticoagulants, antiplatelet medications, or nonsteroidal anti-inflammatory drugs that could not be safely discontinued for 4 weeks. Patients were excluded if they had a history of aspirin intolerance or allergy or abnormal blood cell counts (platelet count ,100,000/mL or .500,000/mL, hematocrit ,30%, or white blood cell count .20,000/mL).
Participants were given a 36-day supply of 81-mg aspirin tablets, the dosage recommended for primary prevention by the US Preventive Services Task Force at that time, in 2002 (25) . Participants were instructed to take 1 tablet each day for 14 days. After interviewer-administered assessment of diet and exercise with a modified 24-hour dietary recall and the Stanford 7-Day Physical Activity Recall, participants were instructed to maintain the same dietary and physical activity patterns during the 14 days of aspirin therapy. Foods (caffeine, chocolate, grapes, alcohol) or food supplements known to influence platelet function were disallowed for the week preceding the baseline measurement and during the 14 days of therapy. Aspirin adherence was assessed at the postaspirin visits with a modified Hill-Bone compliance questionnaire (26) 
]. All blood tests were performed after participants had fasted for 12 hours overnight. Serum glucose, total cholesterol, high-density lipoprotein cholesterol, and triglyceride levels were measured directly. Low-density lipoprotein cholesterol level was estimated with the Friedewald formula. Diabetes was defined as having a fasting plasma glucose level of $126 mg/dL (7 mmol/L), taking a glucoselowering agent, or self-report.
The study was approved by the institutional review board of the Johns Hopkins Medical Institutions and was monitored by an external data and safety monitoring board. Written informed consent was obtained from all participants.
Platelet function testing
Platelet function testing was performed at baseline and after 14 days of aspirin. Measurement variation was minimized by having the same technician process the same participant's samples on the same equipment for the pre-and post-aspirin therapy visits. Blood was obtained from venipuncture and collected into vacutainer tubes containing EDTA (for complete blood cell counts) or 3.2% sodium citrate [for platelet function testing, fibrinogen levels, and von Willebrand factor (vWF)] after the first 4 mL was discarded. Platelet counts were determined by automated cell counter (ACT-Diff; BeckmanCoulter, Miami, FL). Because both leukocytes and erythrocytes can also partially contribute to platelet aggregation, we studied platelet aggregation in both platelet-rich plasma (PRP) and whole blood to provide a more comprehensive assessment of platelet aggregation for our study (27, 28) .
PRP was prepared from whole blood by centrifugation at 180g for 15 minutes, and platelet-poor plasma was prepared by centrifugation at 2000g for 10 minutes. Platelet counts were adjusted to 200,000/mL by diluting PRP with platelet-poor plasma. Plasma fibrinogen was measured on an automated optical clot detection device (Behring Coagulation System; Dade-Behring, Newark, DE). Plasma vWF was determined with a commercially available enzyme-linked immunosorbent assay (DiaPharma, West Chester, OH). Optical aggregometry in PRP was measured in a four-channel PAP-4 Aggregometer (Horsham, PA) after samples were stimulated with collagen (1 and 5 mg/mL), adenosine diphosphate (ADP 2 and 10 mM), or AA (1.6 mM).
Whole blood impedance aggregometry was measured in a Chrono-Log dual-channel lumi-aggregometer (Havertown, PA) after samples were stimulated with collagen (1 and 5 mg/mL), ADP (10 mM), or AA (0.5 mM). In addition, one whole blood sample was incubated with aspirin (20 mM for 20 minutes) in vitro before stimulation with AA to determine ability of aspirin to directly inhibit COX-1 in vitro. Peak platelet responses within 5 minutes of agonist stimulation were recorded for aggregation (as a percentage of aggregation for PRP and ohms for whole blood). For PRP aggregometry specifically, before agonist is added, aggregation is 0%. After agonist is added, platelets fall out of suspension, and optical density of the PRP changes. The percentage change in optical density is measured vs platelet-poor plasma, which serves as a blank and represents 100% aggregation. Whole blood was loaded into prefabricated proprietary cartridges (PFA-100, Dade-Behring) containing a combination of collagen and epinephrine as platelet agonists. Platelet function analyzer closure time (PFA-100 CT) (the time for cessation of blood flow caused by formation of a platelet plug) was recorded in seconds. The maximum time allowed for closure was 300 seconds.
A minimum of 4 mL of urine was collected from the participants at each visit. Urinary 11-dehydro TXB2 was quantified by commercially available ELISA and normalized to urinary creatinine.
Statistical analysis
Variable distributions were examined for normality with the Kolmogorov-Smirnov statistic. Nonnormal continuous variables were appropriately transformed. Categorical variables were examined with contingency table arrays and the x 2 statistic. Generalized estimating equation multivariable linear and logistic regression analyses correcting for nonindependence of families were used to determine the association of diabetes status with post-aspirin therapy platelet aggregation measures in unadjusted models (model 1), after sex, age, race, BMI, smoking, platelet counts, and fibrinogen level were controlled for (model 2), and after additional adjustment for preaspirin platelet measures (model 3). All covariates were prespecified according to the published literature on the biological determinants of platelet aggregation. For analysis of PFA-100 CT, the vWF level was an additional covariate because it is known to be related to PFA-100 CT. The relationship of diabetes status to all platelet aggregation measures did not differ by sex, before or after aspirin therapy (P . 0.05 for interaction), so pooled results are presented.
All significance testing was two-tailed with a of 0.05, and data were analyzed in SAS version 9.2 (SAS Institute Inc., Cary, NC).
Results

Population characteristics
The study population included 2113 participants, of whom 8.3% had diabetes, and 57.7% were women. Participants with diabetes were more likely to be African American, have obesity, and be older with higher systolic and diastolic blood pressure than those without diabetes (Table 1) . White blood cell count, fasting glucose, triglyceride, vWF, and fibrinogen levels were significantly higher in the diabetes group (P , 0.05), whereas hematocrit levels were slightly higher in the group without diabetes.
All participants returned for follow-up. Pill count and self-reported nonadherence showed that 82% of participants had 100% adherence to aspirin, and only 2% missed more than two doses. All participants had taken a dose in the 24 hours preceding the postaspirin measurements.
Among the 175 participants with diabetes in our study, 144 (82%) had already been diagnosed with diabetes before study enrollment and 31 (18%) had undiagnosed diabetes that was identified at the first study visit. The mean duration of diabetes for the 144 participants with known history of diabetes was 7.1 6 6.4 years (range 0.3 to 34 years). The majority of participants with diabetes were on oral glucose-lowering medications only (57%), compared with those on insulin only (5%), both insulin and oral glucose-lowering medications (5%), and no glucose-lowering medications (33%). Although type of diabetes was not specifically ascertained in the GeneSTAR cohort, almost all participants were diagnosed with diabetes after the age of 25 years and were considered to have type 2 diabetes (29). In three participants, the diagnosis occurred at a younger age, and the possibility of type 1 diabetes cannot be excluded.
Platelet aggregation before aspirin
In unadjusted analyses, in vivo measures (urinary TXB2 levels) were higher in participants with vs without diabetes at baseline (median [interquartile range (IQR)] 182 (114 to 305) vs 138 (84 to 231) ng/mmol creatinine, P , 0.0001) (Fig. 1) . Overall, platelet aggregation to all in vitro agonists in whole blood (Fig. 2) and in PRP except ADP 10 mM (Fig. 3) was similar between those with and those without diabetes (all Ps . 0.05). A longer PFA-100 CT was observed in people with than without diabetes (P = 0.003) (Fig. 4) . There was no difference in measurable (nonzero) platelet aggregation to AA with 20 mM of aspirin added in vitro to whole blood between those with and without diabetes (96% vs 97.3%, P = 0.27). Platelet aggregation after aspirin Platelet aggregation in vivo was markedly reduced in participants with and without diabetes after aspirin (Fig. 1 ), yet a greater decrement in urinary TXB2 levels was found in those with than in without diabetes [median (IQR) 2130 (2234 to 278.4) vs 298.3 (2179 to 251.6) ng/mmol creatinine, respectively, P , 0.0001]. However, concentrations of TXB2 remained higher in participants with vs without diabetes after aspirin [median (IQR) 41.7 (27.9 to 69.7) vs 32.5 (20.7 to 52.3) ng/mmol creatinine, respectively, P = 0.0002]. For in vitro platelet assays measuring the direct COX-1 pathway, most participants with and without diabetes (91.4% and 93.3%, respectively, P = 0.33) had complete inhibition of platelet reactivity (zero aggregation to 0.5 mM AA) after aspirin in whole blood. Similarly, platelet reactivity to collagen and ADP in both whole blood (Fig. 2) and PRP (Fig. 3) was not different after aspirin by diabetes status. When 20 mM of aspirin was added in vitro in whole blood, no significant difference was noted in the percentages of measurable aggregation to AA between participants with or without diabetes after aspirin (1.2 vs 0.4%, P = 0.17). In addition, PFA-100 CT was similar between groups after aspirin (Fig. 4) .
Multivariable regression analyses
In unadjusted regression analyses, the in vivo urinary TXB2 levels were higher in those with vs without diabetes after aspirin (0.24 6 0.08 ng/mmol creatinine, P 5 0.004) (Model 1, Table 2 ). The diabetes group continued to have modestly higher levels of TXB2 after aspirin in the model adjusted for age, sex, race, BMI, smoking status, platelet count, and fibrinogen levels (0.18 6 0.09 ng/mmol creatinine, P 5 0.04) (Model 2, Table 2 ). Additional sensitivity analyses, modeled separately for women to adjust for menopausal status, premenopausal use of oral contraceptive pills, and postmenopausal use of hormonal replacement therapy, did not change these results. Interestingly, the difference in urinary TXB2 levels after aspirin was attenuated and became statistically nonsignificant after additional adjustment for vWF in the regression model (0.176 0.09 ng/mmol creatinine, P = 0.05; data not shown). The in vitro platelet aggregation to collagen (1 and 5 mg/mL) and ADP 10 mM in whole blood and to collagen (1 and 5 mg/mL) and ADP 2 mM in PRP was similar in those with and without diabetes after aspirin in adjusted analyses (model 2, all Ps . 0.05). However, participants with diabetes had lower platelet reactivity to ADP 10 mM in PRP compared with those without diabetes after aspirin (P = 0.01) (model 2, Table 2 ).
After additional adjustment for preaspirin levels, none of the postaspirin in vivo or in vitro measures of platelet reactivity (or PFA-100 CT) demonstrated significant differences between the diabetes and nondiabetes groups (model 3, all Ps . 0.05). Regression analyses modeling the relationship of diabetes status and platelet aggregation to AA after aspirin therapy could not be performed because most participants had zero aggregation.
Discussion
Our study demonstrates that people with diabetes have higher in vivo platelet activation compared with those without diabetes both before and after aspirin. Although the absolute reduction in in vivo platelet activation after aspirin is greater in participants with vs without diabetes, the percentage reduction in urinary TXB2 levels is not different between the two groups. Furthermore, people with and without diabetes had similar in vitro platelet Figure 2 . (A) In vitro whole blood platelet aggregation to collagen 1 mg/mL was similar in adults with vs without diabetes both before aspirin (mean 6 SD 19.5 6 6.1 V vs 19.6 65.8 V, P = 0.94) and after aspirin (mean 6 SD 6.7 6 5.3 V vs 6.2 6 5.3 V, P = 0.31). (B) In vitro whole blood platelet aggregation to collagen 5 mg/mL was similar in adults with vs without diabetes both before aspirin (mean 6 SD 26.1 6 6.7 vs 26.2 6 6.8, V, P = 0.77) and after aspirin (mean 6 SD 23.9 6 7.5 vs 23.7 6 6.9, V, P = 0.67). (C) In vitro whole blood platelet aggregation to ADP 10 mM was similar in adults with vs without diabetes both before aspirin (mean 6 SD 12.8 6 5.9 vs 12.6 6 5.6 V, P = 0.59) and after aspirin (mean 6 SD 12.8 6 6.4 vs 12.3 6 5.9 V, P = 0.24).
doi: 10.1210/jc.2018-01254 https://academic.oup.com/jcemreactivity to multiple agonists before and after aspirin and with a similar decrement in platelet response. These results suggest that intrinsic platelet function and response to aspirin do not differ by diabetes status and potentially refutes previous reports of "aspirin resistance" in people with diabetes. The increased in vivo platelet activation in those with diabetes in our study is probably caused by factors that are not intrinsic to the platelet itself, as evidenced by the similar in vitro platelet function. Endothelial dysfunction is an example of a defect that is extrinsic to the platelet and has been implicated as a contributor to the increased platelet activation in diabetes (30) . Consistent with previous studies, participants with diabetes in our study had higher levels of vWF compared with those without diabetes before aspirin therapy (31) . Of note, the difference in urinary TXB2 levels after aspirin therapy between those with and without diabetes became statistically nonsignificant after we adjusted for vWF levels in regression analysis. This exploratory finding In vitro PRP platelet aggregation to collagen 1 mg/mL was similar in adults with vs without diabetes both before aspirin (73.8% vs 73.9%, P = 1) and after aspirin (68.4% vs 66.6%, P = 0.63). (B) In vitro PRP platelet aggregation to collagen 5 mg/mL was similar in adults with vs without diabetes before aspirin (mean 6 SD 81.4% 6 17.3% vs 81.8% 6 19%, P = 0.83) and after aspirin (mean 6 SD 29.6% 6 23.2% vs 30.3% 6 22%, P = 0.70). (C) In vitro PRP platelet aggregation to ADP 2 mM was similar in adults with vs without diabetes before aspirin (mean 6 SD: 41.3% 6 27.7% vs 42.9% 6 27.2%, P = 0.47) and after aspirin (mean 6 SD 33.2% 6 17.8% vs 34.7% 6 17.6%, P = 0.28). (D) In vitro PRP platelet aggregation to ADP 10 mM was lower in adults with vs without diabetes before aspirin (mean 6 SD: 75.0% 6 17.4% vs 78.1% 6 15.6%, P = 0.02) and remained slightly lower after aspirin (mean 6 SD 65.2% 6 16.2% vs 67.7% 6 13.1%, P = 0.05).
supports the hypothesis that endothelial dysfunction may have a role in the hyperactive platelet phenotype and lower suppression of platelet activation in vivo after aspirin in people with diabetes. Interestingly, elevated concentrations of urinary TXB2 in people treated with aspirin have been associated with an increased risk of future cardiovascular events and death (32) , but more research is needed.
There is a paucity of literature addressing physiological differences in platelet reactivity by diabetes status among patients not on aspirin therapy and without established CVD. Increased in vivo platelet activation, measured by urinary TXB2, has been reported in mixed populations that included participants both with and without CVD (33) (34) (35) (36) (37) (38) . Furthermore, a few studies have demonstrated higher in vitro platelet reactivity in patients with diabetes and without CVD, but results are inconsistent (38) (39) (40) . The inconclusive literature about in vitro platelet reactivity in patients with diabetes largely reflects differences in laboratory methods used to assess the in vitro platelet reactivity in those studies (38, 40, 41) . A systematic review of 31 studies examining platelet reactivity in participants treated with aspirin showed a higher prevalence of high on-treatment platelet reactivity in participants with vs without diabetes (21.9% and 15.8%, respectively), with a pooled relative risk of 1.36 (95% CI, 1.08 to 1.71) (42) . However, methods used to measure platelet reactivity varied widely between those 31 studies (i.e., platelet aggregation to arachidonic acid, ADP, or collagen measured by light transmission aggregometry; PFA-100 CT, or rapid platelet function assay), and the majority of participants in these studies had established CVD, in contrast to our study, where participants had no history of CVD.
Previous randomized, controlled primary prevention trials and meta-analyses of low-dose aspirin among people with diabetes have not demonstrated consistent benefit in reducing cardiovascular events (4, 5, 7, 43, 44) . A meta-analysis of seven large trials specifically in patients with diabetes showed lack of overall benefit of aspirin use for primary prevention of CVD and no increase in major bleeding (43) . Recently, the Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes follow-up study showed an increased risk of gastrointestinal bleeding with aspirin use for primary prevention in patients with diabetes after a 10-year follow-up period (2% aspirin vs 0.9% placebo, P = 0.03) (5) . In contrast, meta-analyses of studies in the general population have suggested a similar effect of aspirin therapy on reduction of cardiovascular events in those with and without diabetes (4) . The Antithrombotic Trialists' study collaborators showed a pooled relative risk reduction of 12% in serious vascular events with use of aspirin as a primary prevention strategy in the general population (0.51% aspirin vs 0.57% placebo events per year, P = 0.0001) and a similar net benefit in those with and without diabetes (4). Although sex differences in the platelet response to aspirin have been reported in the general population (45), we found no interactions by sex in the relationship of diabetes status to platelet aggregation in our study. In clinical practice, balancing the risk and benefits of low-dose aspirin for primary prevention must be considered in all people, with and without diabetes. Future research is needed to identify the subgroups of people who are most likely to benefit from aspirin as a primary prevention measure.
A strength of our study is the detailed measurement of platelet aggregation both before and after aspirin, in a large and well-characterized cohort of patients with no personal history of CVD who are at high risk for CVD based on family history of early-onset coronary artery disease (24) . The comprehensive assessment of platelet function allowed us to identify differences in both in vivo and in vitro platelet response to aspirin and explore direct and indirect COX-1 pathways in whole blood and PRP. Participants also had high adherence to aspirin in our study.
Limitations include the potential lack of generalizability of our results to patients with a different cardiovascular risk profile compared with our study participants. Diabetes was defined based on fasting glucose and use of a glucose-lowering agent in the GeneSTAR cohort. However, information about A1C and 2-hour glucose levels from an oral glucose tolerance test may have reduced potential misclassification of undiagnosed diabetes. We did not have information about the severity of hyperglycemia and prevalence of diabetic complications, which may also contribute to platelet activation and response to aspirin.
In conclusion, our study demonstrates that the platelet response to low-dose aspirin is similar regardless of diabetes status and refutes the notion of physiological "aspirin resistance" in diabetes. However, although people with diabetes may have higher levels of in vivo platelet measures after aspirin, no differences were observed in any of the in vitro platelet measures by diabetes status after aspirin. Additional studies characterizing differences in factors extrinsic to the platelet among people with and without diabetes can ultimately provide insights into in vivo platelet function and the appropriate use of aspirin for people with diabetes in the future. c Logistic regression analyses were performed on these dichotomous aggregation outcomes.
